Navigation Links
Researchers identify novel pathophysiologic mechanism responsible for autoimmunity
Date:4/25/2011

(Boston) Researchers from Boston University School of Medicine (BUSM) have discovered that human proteins with an affinity for Dermatan Sulfate (DS) have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DSautoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models. These findings, which appear in two back-to-back papers in the May issue of the American Journal of Pathology, provide a promising tool for discovery of autoantigens, molecular diagnosis of autoimmune diseases and development of cause-specific therapies.

Autoimmune diseases are the third most common category of disease in the United States after cancer and heart disease; they affect approximately 14-22 million persons. Autoimmune diseases are among the most poorly understood medical conditions, although it is well accepted that they are caused by aberrant immune responses directed at endogenous molecules and tissues of the body. Autoimmune diseases encompass a wide spectrum of clinical presentations, and more than 80 types have been classified, based primarily on systemic or organ-specific involvement. Common systemic autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis and Sjgren's syndrome; localized diseases include type 1 diabetes, multiple sclerosis, and Graves' disease.

According to the researchers, both precise diagnosis and development of cause-directed therapies remain challenging. A major hurdle has been the lack of understanding of etiologically inciting molecular and cellular events and key pathophysiologic mechanisms that lead to autoimmunity.

Studying patients with autoimmune diseases, the researchers discovered patient-specific complex autoantigen patterns that were more diverse than previously thought, indicating significant pathological heterogeneity even
'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers report widespread use of medications among pregnant women
2. Couch-Potato Kids: It Shows in Their Eyes, Researchers Say
3. Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find
4. Women Taking Calcium Supplements May Risk Heart Health, Researchers Say
5. Limiting carbs, not calories, reduces liver fat faster, UT Southwestern researchers find
6. Mutated gene found in dog disease the same in humans, MU researchers find
7. Researchers inject nanofiber spheres carrying cells into wounds to grow tissue
8. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
9. Whales Not Just Singing the Same Old Song, Researchers Say
10. Boston University researchers find most substance-dependent individuals report poor oral health
11. University of Granada researchers make the first bioartificial organ in Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... FL (PRWEB) December 26, 2014 India ... health insurance in the USA, announced today a new ... assist members in choosing the right plan for their ... the complexity out of the selection process when choosing ... by age group with only a few clicks. Many ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Autism spectrum disorder (ASD) is a ... has strong genetic underpinnings, it is also a mix ... many medical disorders and syndromes, the nature of such ... one in 150 children suffers from ASD, and it,s ...
... cj Advertising,s employees lend a hand to the Arthritis Foundation, fellow ... ... -- Nashville-based cj Advertising and its charity fundraising initiative, Camels ... helping raise funds for the Arthritis Foundation and fund research toward ...
... provider, announced that it has acquired Key Instruments, Inc. Terms ... flow meter manufacturer based in Trevose, PA which offers precision ... flow meters, electronic flow meters, and flow control valves for ... ...
... method of accelerated tissue healing is showing its worth in soft-tissue repair, ... ... It was first used by dental surgeons about 15 years ago to ... Rich Plasma (PRP) therapy is today being applied in Singapore as ...
... President Al Gore Endorses Trans-Pacific Collaboration to Promote Use ... Cell-Based TherapiesSOUTH SAN FRANCISCO, Calif., and KYOTO, Japan, April ... for iPS Cell Research and Application (CiRA), today ... basic research, development and application of induced pluripotent stem ...
... BlackBerry® is a Microsoft licensed solution to allow BlackBerry® devices ... for BlackBerry® solution is ideal for organisations or businesses that ... Microsoft Exchange Server, Kerio MailServer, Zimbra Collaboration Suite or the ... ...
Cached Medicine News:Health News:Occupational Therapists Use Sensory Integration to Help Autistic Children Find Fitting Social Behaviors 2Health News:Occupational Therapists Use Sensory Integration to Help Autistic Children Find Fitting Social Behaviors 3Health News:Camels with a Cause Helps Ease the Pain of Arthritis 2Health News:Camels with a Cause Helps Ease the Pain of Arthritis 3Health News:Camels with a Cause Helps Ease the Pain of Arthritis 4Health News:Brooks Instrument Acquires Flow Products Supplier Key Instruments 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 3Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 4Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 2Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 3Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 4Health News:iZumi Bio and Kyoto University Form Collaboration to Advance Induced Pluripotent Stem Cell Technology 5Health News:NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... HIGHLIGHTS :2012 Results (all percentages are to comparable periods ... 5% to $665 million, a new quarterly high. Q1 sales grew ... growth of 4% and 1%, respectively.  Acquisitions contributed 4% to sales ... sales by 2%. , Q1 2012 reported diluted ...
... LAKE SUCCESS, N.Y., April 24, 2012  Polar ( www.polarusa.com ... training technology, today announced the appointment of Herb Baer ... role, Baer will be responsible for the overall direction ... of the business including consumer fitness, running, cycling, physical ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13Herb Baer Appointed President of Polar USA 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: